Summary
BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. The company is also developing Renevia to facilitate cell transplantation; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccine; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. The company’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. The company’s products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.
BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
BioTime Inc, Medical Equipment, Deal Details 12
Venture Financing 12
LifeMap Solutions Raises US$5 Million In Seed Financing 12
Partnerships 12
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
BioTime Enters Into Distribution Agreement With USCN Life Science 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
Biotime Amends Licensing Agreement With University of Utah 17
BioTime Enters Into Option Licensing Agreement With USCN Life Science 18
Equity Offering 19
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 19
BioTime to Raise up to USD25 Million in Private Placement of Shares 20
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 21
OncoCyte Raises USD3.2 Million in Private Placement of Units 22
OncoCyte Raises USD7.3 Million in Private Placement of Units 23
BioTime Raises USD5 Million in Private Placement of Shares 25
BioTime Raises USD20.4 Million in Private Placement of Shares 26
OncoCyte Raises USD3.3 Million in Private Placement of Shares 27
BioTime Completes Private Placement Of Shares For US$6.4 Million 27
BioTime Announces Public Offering Of Shares For Up To US$15 Million 28
BioTime Completes Public Offering Of Shares For US$3.5 Million 29
BioTime Completes Private Placement Of Units For US$9 Million 30
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 31
BioTime Announces Private Placement Of Common Stock 33
BioTime Completes Private Placement For US$3.6 Million 33
Acquisition 34
OrthoCyte Completes Acquisition Of Glycosan BioSystems 34
BioTime Inc - Key Competitors 36
Key Employees 37
Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Financial Announcements 40
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 40
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 42
Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 45
Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 46
Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments 48
May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 50
Corporate Communications 53
Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 53
Oct 31, 2016: BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development 54
Product News 55
May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 55
Aug 15, 2016: BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine 56
Jun 28, 2016: Mount Sinai Launches Mobile Healthcare App Developed with LifeMap Solutions, a subsidiary of BioTime 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List of Tables
BioTime Inc, Medical Equipment, Key Facts, 2016 1
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
LifeMap Solutions Raises US$5 Million In Seed Financing 12
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
BioTime Enters Into Distribution Agreement With USCN Life Science 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
Biotime Amends Licensing Agreement With University of Utah 17
BioTime Enters Into Option Licensing Agreement With USCN Life Science 18
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 19
BioTime to Raise up to USD25 Million in Private Placement of Shares 20
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 21
OncoCyte Raises USD3.2 Million in Private Placement of Units 22
OncoCyte Raises USD7.3 Million in Private Placement of Units 23
BioTime Raises USD5 Million in Private Placement of Shares 25
BioTime Raises USD20.4 Million in Private Placement of Shares 26
OncoCyte Raises USD3.3 Million in Private Placement of Shares 27
BioTime Completes Private Placement Of Shares For US$6.4 Million 27
BioTime Announces Public Offering Of Shares For Up To US$15 Million 28
BioTime Completes Public Offering Of Shares For US$3.5 Million 29
BioTime Completes Private Placement Of Units For US$9 Million 30
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 31
BioTime Announces Private Placement Of Common Stock 33
BioTime Completes Private Placement For US$3.6 Million 33
OrthoCyte Completes Acquisition Of Glycosan BioSystems 34
BioTime Inc, Key Competitors 36
BioTime Inc, Key Employees 37
BioTime Inc, Subsidiaries 38
